SurModics to Present Five Posters at the Association for Research in Vision and Ophthalmology Meeting
"ARVO is an important meeting for SurModics, and we are pleased to showcase our scientific progress with customers and physicians," said Paul Lopez, President of SurModics' Ophthalmology Division. "SurModics has made significant advances with our sustained drug delivery platforms in the past year. The posters we will be presenting are the culmination of countless efforts by the entire team at SurModics, both in California and in Minnesota. The progress we have made with these technologies is reflected in the strong customer interest in our platforms and capabilities."
Two of the posters to be presented will demonstrate the feasibility of delivering bioactive proteins from SurModics' sustained delivery systems. Currently, the leading drug for treatment of age related macular degeneration (AMD) is a protein therapeutic that requires repeat intraocular injections.
A third poster will be used to present the preclinical assessment of a sustained release implant designed to provide site specific therapeutic delivery in the subretinal space. This platform is being investigated for a more localized and targeted delivery of compounds for serious back of the eye diseases, such as AMD and Diabetic Macular Edema (DME).
The fourth poster will evaluate the use of a biodegradable implant capable of delivering pharmaceutical agents in a controlled manner.
The final poster will provide 9 month data from the STRIDE (Sustained Triamcinolone Release for Inhibition of Diabetic Macular Edema) Phase I Clinical Study. The STRIDE trial is assessing the safety and tolerability of the I-vation(TM) intravitreal implant with triamcinolone acetonide in patients with DME under an Investigational New Drug application with the U.S. Food and Drug Administration.
About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo(TM) drug delivery polymer matrix as a key component of the first-to-market drug eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products. SurModics is headquartered in Eden Prairie, MN. More information about the company can be found at www.surmodics.com. The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.
Safe Harbor for Forward Looking Statements
Certain statements contained in this press release may be deemed to be forward looking statements under federal securities laws, and SurModics intends that such forward looking statements be subject to the safe harbor created thereby. SurModics does not undertake an obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
SOURCE: SurModics, Inc.
Senior Vice President and Chief Financial Officer